FDA 483 - Nephron Pharmaceuticals Corp. - August 17, 2012
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Nephron Pharmaceuticals Corp., an aseptic fill drug manufacturer in Orlando, FL, was cited for three observations during an FDA inspection. Deficiencies included the quality control unit not following procedures for annual product reviews and field alert reports, inadequate line clearance activities, and a failure to conduct routine re-qualification training for analytical lab employees. These issues indicate a lack of adherence to established written procedures across multiple operational areas.
ID · 20ae3bb3-aeb8-4dc3-a617-03709efbc605